...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of magnetic resonance imaging: JMRI >Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.
【24h】

Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.

机译：使用DCE-MRI和血管大小成像在抗血管生成治疗下评估血管重塑。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To assess vascular remodeling in tumors during two different antiangiogenic therapies with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and vessel size imaging and to evaluate the vessel size index (VSI) as a novel biomarker of therapy response. MATERIALS AND METHODS: In two independent experiments, nude mice bearing human skin squamous cell carcinoma xenografts were treated with a vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) or a multitargeted tyrosine kinase inhibitor (SU11248). Changes in tumor vascularity were assessed by DCE-MRI and vessel size imaging. DCE-MRI data were analyzed applying a two-compartment model (Brix), calculating the parameters Amplitude and k(ep). RESULTS: For both experiments Amplitude decreased significantly in treated tumors while k(ep) did not change significantly. VSI showed controversial results. VSI was significantly increased in SU11248-treated A431 tumors, whereas no changes were found in bevacizumab-treated HaCaT-ras-A-5RT3 tumors. Immunohistology confirmed these results and suggest differences in the maturation of tumor vascularization as a possible explanation. CONCLUSION: DCE-MRI and vessel size imaging provide reliable and supplementing biomarkers of antiangiogenic therapy response. The results of both methods are in excellent agreement with histology. Nevertheless, our results also indicate that vascular remodeling is complex and that a uniform response cannot be expected for different tumors and therapies.
机译：目的：通过动态对比增强磁共振成像（DCE-MRI）和血管大小成像评估两种不同抗血管生成疗法期间肿瘤中的血管重塑，并评估血管大小指数（VSI）作为治疗反应的新生物标记。材料与方法：在两个独立的实验中，对携带人皮肤鳞状细胞癌异种移植物的裸鼠用血管内皮生长因子（VEGF）抑制剂（贝伐单抗）或多靶酪氨酸激酶抑制剂（SU11248）进行处理。通过DCE-MRI和血管大小成像评估肿瘤血管的变化。使用两室模型（Brix）分析DCE-MRI数据，计算参数Amplitude和k（ep）。结果：对于这两个实验，在治疗的肿瘤中振幅均显着降低，而k（ep）并未显着改变。 VSI显示有争议的结果。在SU11248治疗的A431肿瘤中，VSI显着增加，而在贝伐单抗治疗的HaCaT-ras-A-5RT3肿瘤中未发现变化。免疫组织学证实了这些结果，并暗示了肿瘤血管形成成熟的差异可能是一种解释。结论：DCE-MRI和血管大小成像为抗血管生成治疗反应提供了可靠的补充生物标志物。两种方法的结果均与组织学非常吻合。然而，我们的研究结果还表明，血管重塑是复杂的，并且对于不同的肿瘤和治疗方法，无法期望获得统一的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号